Momenta Phama (MNTA) Tops Q1 EPS by 14c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results
May 7, 2020 7:01 AM EDT-- Top-line interim data from nipocalimab Vivacity-MG study expected by Q3 2020 --
-- Full data from Part B of Phase 1/2 study of M254 in ITP expected in Q3 2020 --
-- Initiated IND-enabling studies for M267, a SIFbody candidate targeting CD38 --
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the first quarter ended March 31, 2020.
Despite the... More
